Pfizer’s Billion-Dollar Acquisition Fails to Impress Investors

Pfizer’s recent $7 billion acquisition of biotechnology firm Metsera has triggered a wave of market skepticism rather than celebration. The pharmaceutical giant aims to secure its position in the lucrative obesity treatment market, currently dominated by Novo Nordisk and Eli Lilly. Despite the strategic ambition behind the move, Pfizer’s shares declined 2.83 percent to $25.06 amid elevated trading volume, reflecting significant investor unease.

The transaction provides Pfizer with immediate access to Metsera’s promising pipeline of drug candidates targeting weight management. Under the terms, Pfizer will pay $65.60 per share in cash upfront. Former Metsera shareholders could receive additional payments of up to $20.65 per share, contingent upon achieving specific clinical and regulatory milestones. Read more...